We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Iovance Biotherapeutics Inc (IOVA) USD0.000041666

Sell:$5.90 Buy:$6.05 Change: $0.12 (1.96%)
NASDAQ:1.28%
Market closed |  Prices as at close on 22 January 2025 | Switch to live prices |
Sell:$5.90
Buy:$6.05
Change: $0.12 (1.96%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 January 2025 | Switch to live prices |
Sell:$5.90
Buy:$6.05
Change: $0.12 (1.96%)
Market closed |  Prices as at close on 22 January 2025 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.

Contact details

Address:
825 INDUSTRIAL ROAD, 4TH FLOOR
SAN CARLOS
94070
United States
Telephone:
+1 (650) 2607120
Website:
https://www.iovance.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IOVA
ISIN:
US4622601007
Market cap:
$1.79 billion
Shares in issue:
304.78 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Frederick Vogt
    Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
  • Jean-Marc Bellemin
    Chief Financial Officer
  • Igor Bilinsky
    Chief Operating Officer
  • Friedrich Graf Finckenstein
    Chief Medical Officer
  • Raj Puri
    Chief Regulatory Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.